Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Palbociclib plus hormone therapy guided by circulating ESR1 mutation monitoring in ER-positive/HER2-negative metastatic breast cancer
2016-004360-18Phase 3Active
- Sponsor
- Unicancer
- Start
- Feb 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of palbociclib, fulvestrant, letrozole, anastrozole and exemestane in breast cancer (2 arms), sponsored by Unicancer. Primary endpoint: Hematological safety in patients with bone metastases. Started Feb 2017; status: active.
02
Drugs
palbociclibfulvestrantletrozoleanastrozoleexemestane
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2016-004360-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004360-18.